ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.3075G>T (p.Lys1025Asn)

dbSNP: rs80358551
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV001018476 SCV001179721 uncertain significance Hereditary cancer-predisposing syndrome 2018-10-31 criteria provided, single submitter clinical testing The p.K1025N variant (also known as c.3075G>T), located in coding exon 10 of the BRCA2 gene, results from a G to T substitution at nucleotide position 3075. The lysine at codon 1025 is replaced by asparagine, an amino acid with similar properties. This alteration was identified in an individual with a family history of breast and/or ovarian cancer from Slovakia (Konecny M et al. Breast Cancer Res Treat, 2011 Feb;126:119-30). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
University of Washington Department of Laboratory Medicine, University of Washington RCV001018476 SCV003850363 likely benign Hereditary cancer-predisposing syndrome 2023-03-23 criteria provided, single submitter curation Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673).
All of Us Research Program, National Institutes of Health RCV000113131 SCV004845102 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 2 2023-10-27 criteria provided, single submitter clinical testing This missense variant replaces lysine with asparagine at codon 1025 of the BRCA2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in 1 individual affected with breast or ovarian cancer; this individual carried a second BRCA2 variant known to be pathogenic that could explain the observed phenotype (PMID: 16168118). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Breast Cancer Information Core (BIC) (BRCA2) RCV000113131 SCV000146165 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 2 2002-05-29 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.